Press Releases Xintela AB

Equities

Delayed Nasdaq Stockholm Other stock markets 11:23:10 26/06/2024 BST			5-day change	1st Jan Change
0.298 ^SEK	-0.67%		+4.20%	+9.96%

05-24	Xintela AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-23	Xintela and EQGen Biomedical to Collaborate to Develop EQSTEM Stem Cell Treatment for Horses	CI

Xintela: Closing in on the first license agreement	05-29	AQ
Xintela AB Interim Report January - March 2024	05-24	AQ
Xintela and EQGen Biomedical to collaborate to develop EQSTEM stem cell treatment for horses	05-23	AQ
Xintela AB publishes Annual Report 2023	04-17	AQ
Xintela: Awaiting results in trials and discussions	02-29	AQ
Xintela AB Year-end Report 2023	02-28	AQ
Xintela appoints Lucienne Vonk as Chief Scientific Officer	02-19	AQ
Targinta's CEO to BioStock: "Strong interest in ADCs in 2023"	01-22	AQ
Xintela newsletter, No. 1 2024	01-19	AQ
First patient dosed in Xintela's clinical study on difficult-to-heal leg ulcers	12-21	AQ
Xintela publishes efficacy results with EQSTEM from preclinical equine OA study	12-20	AQ
Västra Hamnen Corporate Finance initiates coverage of Xintela	12-04	AQ
Xintela’s integrin marker carries hidden value	12-01	AQ
Xintela changes Certified Adviser to Carnegie Investment Bank AB (publ)	11-30	AQ
Xintela AB Interim Report January - September 2023	11-24	AQ
Xintela’s stem cell product, XSTEM, has been assessed as safe at all dose levels in knee osteoarthritis clinical study	13/10/23	AQ
Xintela AB Interim Report January - June 2023	30/08/23	AQ
Xintela gets product patent in USA for chondrocyte-based products	15/08/23	AQ
Xintela completes XSTEM dosing at third and final dose level in knee osteoarthritis clinical study	22/06/23	AQ
Xintela publishes positive preclinical results from XSTEM treatment of ARDS	09/06/23	AQ

No results for this search